Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice.

Cardiovascular research - 1 Feb 2014

Dalin Martin G, Zou Zhiyuan, Scharin-Täng Margareta, Safari Roghaiyeh, Karlsson Christin, Bergo Martin O

Abstract excerpt

AIMS: Germ-line mutations in genes encoding components of the RAS/mitogen-activated protein kinase (MAPK) pathway cause developmental disorders called RASopathies. Hypertrophic cardiomyopathy (HCM) is the most common myocardial pathology and a leading cause of death in RASopathy patients. KRAS mu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ventricular Function, Left
Share to Cardiomyopathy, Hypertrophic, Familial
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Integrases

Share to Myocardial Infarction

Share to Myosin Heavy Chains

Share to Ultrasonography

Share to Ventricular Myosins

Source

Identifiers

PMID: 24259500
DOI: 10.1093/cvr/cvt260

Genes

KRAS
HRAS
RAF1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24259500-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice.PMID 24259500Read ↗

RASopathies and Cardiac Complications: Insights into Mechanisms, Diagnosis, and Innovative Treatments.Semantic proximity Read ↗

Mavacamten improves energy balance in a pre-clinical model of RASopathy-associated hypertrophic cardiomyopathySemantic proximity Read ↗

Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathies.Semantic proximity Read ↗

Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.Semantic proximity Read ↗

Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice <i>in vivo</i>Semantic proximity Read ↗

H-Ras Isoform Mediates Protection Against Pressure Overload-Induced Cardiac Dysfunction in Part Through Activation of AKT.Semantic proximity Read ↗

RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.Semantic proximity Read ↗

KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.Semantic proximity Read ↗

Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in miceSemantic proximity Read ↗

Cardiomyocyte hyperplasia and immaturity but not hypertrophy are characteristic features of patients with RASopathies.Semantic proximity Read ↗

Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes.Semantic proximity Read ↗

MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.